Novorax CEO Stanley Erck attends a gathering with President Donald Trump, members of the Coronavirus Task Force and pharmaceutical executives within the Cabinet Room of the White House, Monday, March 2, 2020, in Washington.
Andrew Harnik | AP
Workers on the entrance strains of the coronavirus pandemic will be first to obtain a vaccine and that could come as soon as later this yr, Stanley Erck, CEO of vaccine growth firm Novavax, mentioned Tuesday.
Novavax introduced Monday that it has launched part 1 scientific trials of its coronavirus vaccine candidate and it expects preliminary ends in July.
“I think everybody agrees that the first broad distribution will be to the front line workers, the health care workers,” he mentioned on CNBC’s “Squawk Alley.” “If our phase two data support the safety and immunogenicity that we hope it will and we’re able to see a signal for efficacy, it’s possible that that first line would be vaccinated some time in the fourth quarter of this year.”
Novavax is among the many newest firms to hitch the race for a coronavirus vaccine as the world’s largest drugmakers and biotech firms pause analysis into different illnesses to speed up growth of a treatment for Covid-19. The virus has contaminated greater than 5.5 million individuals around the globe because it emerged in Wuhan, China about six months in the past.
The house of firms vying to provide a profitable vaccine is more and more crowded. It consists of massive and small drugmakers and biotech firms, such as Moderna, Pfizer, Johnson & Johnson, AstraZeneca, Sanofi, GlaxoSmithKline and Merck.
Novavax has an extended highway to show that its vaccine candidate is each protected for human use and truly efficient in combating the coronavirus. Erck mentioned the part one trial will affirm security of the potential vaccine and the part two trial will decide whether or not it is efficient.
Novavax, like different firms growing a vaccine candidate, has begun to ramp up its capacity to fabricate its potential vaccine earlier than it has been accepted to shave months off the supply date, if it proves protected and efficient, Erck mentioned.
“Our target for next year is quite ambitious, but we think doable, which is to produce over a billion doses of vaccine,” he mentioned. “We’d like to do it in various continents. We’d like to do it in Europe, the U.S., perhaps India and in Asia. It’s an aggressive goal”
Pricing on any potential vaccine stays unknown. Erck mentioned his firm plans to cost its potential vaccine on a tiered method primarily based on affordability.
“There’s got to be broad distribution. There’s got to be equitable access,” he mentioned. “There will certainly be tiered pricing depending upon affordability so that the vaccine can be used globally.”
Novavax introduced earlier this month that the European nonprofit Coalition for Epidemic Preparedness Innovations will make investments as much as $384 million to speed up growth of the corporate’s potential vaccine.
“We do know that this is one of the largest opportunities or obligations to distribute vaccines globally. We’re talking billions of doses. It’s never been done before,” Erck mentioned. “There’s lots of ways to go down this pathway none of which have been well defined yet. We’re only in this business for four months now.”